Profusa Lowers Note Conversion Price Floor to $0.20 in Amendment With NorthView Sponsor
Profusa amended its agreement with NorthView Sponsor, lowering the note conversion price floor to $0.20 per share. The conversion price will be the greater of $0.20 or the prior day's closing price. The change applies to conversions on or after the amendment's effective date, November 5, 2026.
How this was made

The 30-second read
Why it matters
The amendment lowers the floor price, which could lead to more conversions and share dilution, but the immediate market reaction is likely muted.
Market read
Micro‑cap biotech news with limited broader market impact.
What to watch
Potential future financing needs could increase conversion likelihood.
Background
Profusa filed an 8‑K on Nov 6 detailing the amendment to its note conversion terms with NorthView Sponsor.
Ticker impact
Profusa amended its Note Conversion Agreement, lowering the conversion price floor to $0.20 per share.
possible modest downward pressure as investors price in potential dilution.
Amendment changes conversion terms; impact depends on conversion likelihood.
Market effects
May affect other biotech firms with similar convertible note structures.
Limited to US biotech microcap segment.
Minimal.
Counterpoint
If conversion remains unlikely, the amendment may have negligible impact on price.
Key entities
- companyProfusa, Inc.
Biotech company issuing convertible notes.
- entityNorthView Sponsor
Counterparty to the note amendment.